Iloperidone: a new option for the treatment of schizophrenia

References

• Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med.2(5), e141 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron28(2), 325–334 (2000).
   PubMed Web of Science ®Google Scholar
• Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950–2005. Schizophr. Res.98(1–3), 287–294 (2008).
   PubMed Web of Science ®Google Scholar
• Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J. Gen. Intern. Med.21(11), 1133–1137 (2006).
   PubMed Web of Science ®Google Scholar
• Ucok A, Polat A, Cakir S, Genc A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur. Arch. Psychiatry Clin. Neurosci.256(1), 37–43 (2006).
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L et al. The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry66(9), 1122–1129 (2005).
   PubMed Web of Science ®Google Scholar
• Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Components and correlates of family burden in schizophrenia. Psychiatr. Serv.57(8), 1117–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am. J. Med.120(4 Suppl. 1), S26–S31 (2007).
   PubMedGoogle Scholar
• Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry69(1), 106–113 (2008).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J.6(1), 16–21 (2006).
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry20(1), 15–27 (2005).
   PubMed Web of Science ®Google Scholar
• Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry67(10), 1511–1521 (2006).
   PubMed Web of Science ®Google Scholar
• Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry47(1), 27–38 (2002).
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Hamilton SH, Crawford AM et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol.7(2), 125–137 (1997).
   PubMed Web of Science ®Google Scholar
• Casey DE. The relationship of pharmacology to side effects. J. Clin. Psychiatry58(Suppl. 10), 55–62 (1997).
   PubMed Web of Science ®Google Scholar
• Tandon R. Pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res.100(1–3), 20–38 (2008).
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry158(3), 360–369 (2001).
   PubMed Web of Science ®Google Scholar
• Remington G, Chong S-A. Conventional versus novel antipsychotics: changing concepts and clinical implications. J. Psychiatry Neurosci.24(5), 431–441 (1999).
   PubMed Web of Science ®Google Scholar
• Di Pietro NC, Seamans JK. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry40(Suppl. 1), S27–S33 (2007).
   PubMedGoogle Scholar
• Lehman AF, Lieberman JA, Dixon LB et al.Practice Guideline for the Treatment of Patients With Schizophrenia (2nd Edition). American Psychiatric Association, Arlington, VA, USA (2004).
   Google Scholar
• Risperdal package insert. Janssen Pharmaceutica, Titusville, NJ, USA (2008).
   Google Scholar
• Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve. Clin. J. Med.74(8), 597–606 (2007).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry13(1), 27–35 (2008).
   PubMed Web of Science ®Google Scholar
• Zyprexa package insert. Eli Lilly and Company, Indianapolis, IN, USA (2008).
   Google Scholar
• Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am. J. Epidemiol.164(7), 672–681 (2006).
   PubMed Web of Science ®Google Scholar
• Seroquel package insert. AstraZeneca, Wilmington, DE, USA (2008).
   Google Scholar
• Pae C-U, Kim JJ, Lee C-U et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J. Clin. Psychiatry68(3), 399–405 (2007).
   PubMedGoogle Scholar
• Geodon package insert. Pfizer, New York, NY, USA (2007).
   Google Scholar
• Eng SM, Strom BL, Faich G et al. Comparative mortality associated with ziprasidone vs. olanzapine in real-world use: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Presented at: 161st Annual Meeting of the American Psychiatric Association. Washington, DC, USA, 3–8 May 2008 (Abstract NR5-127).
   Google Scholar
• Abilify package insert. Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan (2007).
   Google Scholar
• Howland RH. Paliperidone extended-release tablets: a new atypical antipsychotic. J. Psychosoc. Nurs. Ment. Health Serv.45(5), 15–18 (2007).
   Google Scholar
• Invega package insert. Janssen LP, Titusville, NJ, USA (2008).
   Google Scholar
• Mossman D, Lehrer DS. Conventional and atypical antipsychotics and the evolving standard of care. Psychiatr. Serv.51(12), 1528–1535 (2000).
   PubMedGoogle Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry8(1), 32 (2008).
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J. Clin. Psychiatry68(Suppl. 1), 12–19 (2007).
   PubMed Web of Science ®Google Scholar
• Tandon R, Belmaker RH, Gattaz WF et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res.100(1–3), 20–38 (2008).
   PubMed Web of Science ®Google Scholar
• Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv. Rev. Psychiatry14(3), 152–164 (2006).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry68(Suppl. 1), 20–27 (2007).
   PubMed Web of Science ®Google Scholar
• Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol.20(6 Suppl.), 6–19 (2006).
   PubMedGoogle Scholar
• De Oliveira IR, Juruena MF. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Ther.31(6), 523–534 (2006).
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand.115(4), 260–267 (2007).
   PubMed Web of Science ®Google Scholar
• Lindenmayer J-P, Jarboe K, Bossie CA, Zhu Y, Mehnert A, Lasser R. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int. Clin. Psychopharmacol.20(4), 213–221 (2005).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J. Clin. Psychiatry68(10), 1492–1500 (2007).
   PubMed Web of Science ®Google Scholar
• Fanapt™ package insert. Vanda Pharmaceuticals, Rockville, MD, USA (2009).
   Google Scholar
• Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry26(3), 553–560 (2002).
   PubMed Web of Science ®Google Scholar
• Mutlib AE, Klein JT. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J. Pharmacol. Exp. Ther.286(3), 1285–1293 (1998).
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci.68(1), 29–39 (2000).
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Feuerbach D, Lötscher E, Schoeffter P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, α2C, 5-HT6, and 5-HT1A receptors. Life Sci.73(9), 1151–1159 (2003).
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology25(6), 904–914 (2001).
   PubMed Web of Science ®Google Scholar
• Corbett R, Griffiths L, Shipley JE et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev.3(2), 120–147 (1997).
   Google Scholar
• Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J. Clin. Pharmacol.35(7), 713–720 (1995).
   PubMed Web of Science ®Google Scholar
• Sedek G, Wolfgang C. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. Presented at: 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19–24 May 2007.
   Google Scholar
• Wolfgang C. Genotyping facilitates individualized prediction of pharmacokinetic exposure of iloperidone in extensive and poor CYP2D6 metabolizers. Presented at: 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19–24 May 2007.
   Google Scholar
• Baroldi P, Wolfgang C, Fisher D. A pharmacokinetic (PK)–pharmacodynamic (PD) relationship exists for efficacy of iloperidone, a novel investigational atypical antipsychotic agent. Presented at: 160th Annual Meeting of the American Psychiatric Association. San Diego, CA, USA, 19–24 May 2007.
   Google Scholar
• Borison RL, Huff FJ, Griffiths L. Efficacy of 5 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Psychopharmacol. Bull.32, 416 (1996).
   Web of Science ®Google Scholar
• Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia. Initial phase 3 studies. J. Clin. Psychopharmacol.28(2 Suppl. 1), S4–S11 (2008).
   PubMed Web of Science ®Google Scholar
• Hamilton J, Wolfgang C, Feeney J, Baroldi P, Polymeropoulos MH. The efficacy of iloperidone is comparable to risperidone in analyses of a placebo- and risperidone-controlled clinical trial for schizophrenia. Presented at: 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, USA, 26–21 May 2009.
   Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J. Clin. Psychopharmacol.28(2 Suppl. 1), S20–S28 (2008).
   PubMed Web of Science ®Google Scholar
• Kane JM, Lauriello J, Laska E, DiMarino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J. Clin. Psychopharmacol.28(2 Suppl. 1), S29–S35 (2008).
   PubMed Web of Science ®Google Scholar
• Torres R, Nasrallah HA, Di Marino M, Baroldi P. Iloperidone versus haloperidol as long-term maintenance treatment for patients with schizophrenia or schizoaffective disorder. Presented at: 161st Annual Meeting of the American Psychiatric Association. Washington, DC, USA, 3–8 May 2008.
   Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone. A pooled analysis of 6-week acute-phase pivotal trials. J. Clin. Psychopharmacol.28(2 Suppl. 1), S12–S19 (2008).
   PubMed Web of Science ®Google Scholar
• Stahl S, Baroldi P, Feeney J, Wolfgang CD. The metabolic profile of iloperidone: a summary of phase II and III schizophrenia trials. Presented at: 161st Annual Meeting of the American Psychiatric Association. Washington, DC, USA, 3–8 May 2008.
   Google Scholar
• Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. North Am.30(3), 437–452 (2007).
   PubMed Web of Science ®Google Scholar
• Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry67(Suppl. 5), 9–14 (2006).
   PubMed Web of Science ®Google Scholar
• Hill CL, Phadke D, Boyce KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. Presented at: 161st Annual Meeting of the American Psychiatric Association. Washington, DC, USA, 3–8 May 2008.
   Google Scholar
• Dziennis S, Habecker BA. Cytokine suppression of dopamine-beta-hydroxylase by extracellular signal-regulated kinase-dependent and -independent pathways. J. Biol. Chem.278(18), 15897–15904 (2003).
   PubMedGoogle Scholar
• Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H. Ciliary neurotrophic factor. J. Neurobiol.25(11), 1436–1453 (1994).
   PubMedGoogle Scholar
• Lin PY, Tsai G. Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia. Schizophr. Res.71(2–3), 353–360 (2004).
   PubMedGoogle Scholar
• Thome J, Durany N, Harsanyi A et al. A null mutation allele in the CNTF gene and schizophrenic psychoses. Neuroreport7(8), 1413–1416 (1996).
   PubMedGoogle Scholar
• Giess R, Maurer M, Linker R et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch. Neurol.59(3), 407–409 (2002).
   PubMedGoogle Scholar
• Lavedan C, Volpi S, Polymeropoulos MH, Wolfgang CD. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics9(3), 289–301 (2008).
   PubMed Web of Science ®Google Scholar
• Lavedan C, Licamele L, Volpi S et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry14(8), 804–819 (2009).
   PubMed Web of Science ®Google Scholar
• Volpi S, Heaton C, Mack K et al. Pharmacogenomic analysis shows differences in markers associated with response between two atypical antipsychotics, iloperidone and ziprasidone, in the treatment of patients with schizophrenia. Presented at: American Society of Human Genetics 57th Annual Meeting. San Diego, CA, USA, 23–27 October 2007.
   Google Scholar
• Volpi S, Potkin SG, Malhotra AK et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psych.70(6), 801–809 (2009).
   Google Scholar
• Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr. Q.74(3), 291–306 (2003).
   PubMed Web of Science ®Google Scholar
• Paulussen AD, Gilissen RA, Armstrong M et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med.82(3), 182–188 (2004).
   PubMed Web of Science ®Google Scholar
• Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation105(16), 1943–1948 (2002).
   PubMed Web of Science ®Google Scholar
• Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol.22(1), 39–43 (2007).
   PubMed Web of Science ®Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med.350(10), 1013–1022 (2004).
   PubMed Web of Science ®Google Scholar
• Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymporphisms in the CERKL gene associated with QT prolongation during iloperidone treatment of patients with schizophrenia. Mol. Psychiatry14(11), 1024–1031 (2009).
   PubMed Web of Science ®Google Scholar
• Bezzina CR, Verkerk AO, Busjahn A et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc. Res.59(1), 27–36 (2003).
   PubMed Web of Science ®Google Scholar